^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

Excerpt:
...phase 2 trial of tisagenlecleucel in adult pts with r/r DLBCL, were analyzed to identify baseline disease and pt characteristics and serum biomarkers that may correlate with efficacy...Compared with pts with normal levels of LDH at pre-infusion, pts with LDH 1-2-fold above the ULN and >2-fold above the ULN had poorer PFS and OS...Pre-infusion high TV, high CRP, high ferritin, and low serum albumin associated with worse OS...Multivariate analyses identified that high levels of pre-infusion LDH, a known marker of tumor burden, metabolic activity, and disease aggressiveness, was associated with NRs at month 3 as well as worse PFS and OS.
DOI:
https://doi.org/10.1182/blood-2019-129107
Trial ID: